-
REFINED ESTIMATES OF THE PERSISTENCE OF VACCINE EFFECTIVENESS INCREASE THE VALUE AND IMPACT OF 4CMENB ADOLESCENT VACCINATION
Aug 11, 2026, 17:16 PM -
ACCEPTANCE OF SURROGATE ENDPOINTS IN ONCOLOGY WITHIN EARLY BENEFIT ASSESSMENT IN GERMANY: AND YES, THERE ARE EXCEPTIONS
Aug 11, 2026, 17:16 PM -
HEALTH UTILITY AND WORK PRODUCTIVITY BURDEN ASSOCIATED WITH CO-OCCURRING ANXIETY AND CHRONIC PAIN AMONG ADULTS REPORTING DEPRESSION IN THE EU5
Aug 11, 2026, 17:16 PM -
RECONSTRUCTING TRIAL-SPECIFIC TIME-ZERO IN REAL-WORLD DATA: A GENETIC ALGORITHM APPROACH TO VALIDATE INDIGO TRIAL OUTCOMES
Aug 11, 2026, 17:16 PM -
VALUATION OF THE CARE PATHWAY BY THE TRANSPARENCY COMMITTEE (TC) (HAUTE AUTORITE DE SANTE): A RETROSPECTIVE REVIEW OF TC OPINIONS FROM JANUARY 2023 TO DECEMBER 2025
Aug 11, 2026, 17:16 PM -
EVALUATING THE TOTAL MEDICAL COSTS OF G-CSF PROPHYLAXIS VERSUS NON-PROPHYLAXIS IN SACITUZUMAB GOVITECAN-TREATED BREAST CANCER PATIENTS IN ASIA
Aug 11, 2026, 17:16 PM -
REIMBURSEMENT UNDER UNCERTAINTY: HOW EUROPEAN HTA ORGANISATIONS MANAGE EVIDENCE GAPS IN ONCOLOGY — A CASE STUDY OF PARP INHIBITORS
Aug 11, 2026, 17:16 PM -
PATIENT DEMOGRAPHICS, TREATMENT, AND QUALITY OF LIFE IN MULTIPLE MYELOMA: A REAL-WORLD SURVEY IN EUROPE
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MYASTHENIA GRAVIS AND GENERALIZED MYASTHENIA GRAVIS IN FRANCE: RELIEF, A CLAIMS-BASED STUDY
Aug 11, 2026, 17:16 PM -
COST UTILITY ANALYSIS OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE VERSUS FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL FOR MODERATE TO VERY SEVERE COPD: A COLOMBIAN PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION AND BUDGET IMPACT OF IMPLEMENTING TACE FOR HEPATOCELLULAR CARCINOMA IN BULGARIA
Aug 11, 2026, 17:16 PM -
FISCAL IMPACT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES A GOVERNMENT EXPENDITURE PERSPECTIVE
Aug 11, 2026, 17:16 PM -
DOES EQ-HWB CAPTURE THE IMPACT OF CAREGIVING? A COMPARATIVE STUDY OF PERCEIVED COMPREHENSIVENESS AMONG CAREGIVERS AND NON-CAREGIVERS
Aug 11, 2026, 17:16 PM -
PLATINUM-BASED ADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH RESECTED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFICACY, HTA ACCEPTABILITY AND ACCESS DIVERGE FOR NEW LUPUS NEPHRITIS THERAPIES IN MOROCCO
Aug 11, 2026, 17:16 PM -
THE SOCIOECONOMIC CONSEQUENCES OF CANCER FOR PATIENTS - ACTIONS NEEDED AND FEASIBLE
Aug 11, 2026, 17:16 PM -
HEALTHCARE COSTS AND ECONOMIC BURDEN OF PATIENTS WITH SPINAL MUSCULAR ATROPHY (SMA) AND RELATED MOTOR NEURON DIAGNOSES IN TURKIYE: A REAL-WORLD DATA ANALYSIS
Aug 11, 2026, 17:16 PM -
THE VALUE OF ADDITIONAL FOLLOW-UP IN ONCOLOGY: A CASE STUDY OF HEALTH ECONOMIC ANALYSIS USING DANTE PHASE III TRIAL DATA COMBINED WITH ROUTINELY COLLECTED ELECTRONIC HEALTH RECORDS (HER)
Aug 11, 2026, 17:16 PM -
UNCERTAINITY IN PIVOTAL CLINICAL TRIALS AND REGULATORY OUTCOME IN EUROPE
Aug 11, 2026, 17:16 PM -
EVALUATING THE IMPACT OF FRANCE'S DEROGATORY DIRECT ACCESS SCHEME:INSIGHTS FROM THE PUBLIC HOSPITALS OF PARIS (AP-HP) FRAMEWORK
Aug 11, 2026, 17:16 PM
